Evidence map›Paper›PMID 38573762›Full record

ArticleJMIR public health and surveillance2024

Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study.

Sophia Themistocleous, Christos D Argyropoulos, Paris Vogazianos, George Shiamakkides, Evgenia Noula, Andria Nearchou, Andreas Yiallouris, Charalampos Filippou, Fiona A Stewart, Markela Koniordou and 27 more

Abstract read
In one paragraph

Article in JMIR public health and surveillance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Sophia ThemistocleousSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0003-3561-0004
Christos D ArgyropoulosSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0002-2090-2162
Paris VogazianosDepartment of Behavioural and Social Sciences, School of Humanities, Social and Education Sciences, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0001-9991-6059
George ShiamakkidesSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0003-2982-169X
Evgenia NoulaSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0009-0008-5799-2289
Andria NearchouSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0009-0009-0279-0521
Andreas YiallourisSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0003-4286-9284
Charalampos FilippouSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0002-9324-1641
Fiona A StewartFaculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.ORCID 0000-0002-1029-5768
Markela KoniordouCollaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.ORCID 0000-0002-6034-1291
Ioannis KopsidasCollaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.ORCID 0000-0001-6499-4807
Helena H AsklingDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0001-5155-9726
Sirkka VeneDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-8655-5845
Amandine Gagneux-BrunonCentre d'investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, Saint-Etienne, France.ORCID 0000-0002-0892-2187
Jana Baranda PrellezoMicrobiology Section, Department of Pharmaceutical Sciences and of Health, Faculty of Pharmacy, Universidad San Pablo-Centro de Estudios Universitarios (CEU), Madrid, Spain.ORCID 0000-0002-9060-9228
Elena Álvarez-BarcoCentre for Experimental Pathogen Host Research, University College Dublin School of Medicine, National University of Ireland, Dublin, Ireland.ORCID 0000-0002-4903-9171
Jon Salmanton-GarcíaFaculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.ORCID 0000-0002-6766-8297
Janina LecklerFaculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.ORCID 0000-0002-8488-4338
Alan J MackenCentre for Experimental Pathogen Host Research, University College Dublin School of Medicine, National University of Ireland, Dublin, Ireland.ORCID 0000-0003-3320-8767
Ruth Joanna DavisDepartment of Diagnostic and Public Health, Infectious Diseases, University of Verona, Verona, Italy.ORCID 0000-0001-9364-6983
Anna Maria AzziniDepartment of Diagnostic and Public Health, Infectious Diseases, University of Verona, Verona, Italy.ORCID 0000-0002-7148-2559
Charis ArmeftisSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0009-0007-8091-6711
Margot HellemansVaccine & Infectious Disease Institute - VAXINFECTIO, Centre of Evaluation of Vaccination,, Faculty of Medicine and Health Science, Universiteit Antwerpen, Antwerp, Belgium.ORCID 0009-0005-2926-1559
Romina Di MarzoEuropean Vaccine Initiative (EVI), Heidelberg, Germany.ORCID 0000-0002-8715-0348
Catarina LuisEuropean Vaccine Initiative (EVI), Heidelberg, Germany.ORCID 0000-0003-2748-4087
Ole F OlesenEuropean Vaccine Initiative (EVI), Heidelberg, Germany.ORCID 0000-0002-3025-2466
Olena ValdenmaiierCentre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-7882-2635
Stine Finne JakobsenCentre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-2586-0248
Pontus NauclérDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-8185-2648
Odile LaunayInserm CIC 1417, I-REIVAC, University Hospital of Cochin-Broca-Hôtel-Dieu, University of Paris-Descartes, Paris, France.ORCID 0000-0003-3242-7247
Patrick MallonCentre for Experimental Pathogen Host Research, University College Dublin School of Medicine, National University of Ireland, Dublin, Ireland.ORCID 0000-0002-4337-6222
Jordi OchandoMicrobiology Section, Department of Pharmaceutical Sciences and of Health, Faculty of Pharmacy, Universidad San Pablo-Centro de Estudios Universitarios (CEU), Madrid, Spain.ORCID 0000-0001-7037-1681
Pierre van DammeVaccine & Infectious Disease Institute - VAXINFECTIO, Centre of Evaluation of Vaccination,, Faculty of Medicine and Health Science, Universiteit Antwerpen, Antwerp, Belgium.ORCID 0000-0002-8642-1249
Evelina TacconelliDepartment of Diagnostic and Public Health, Infectious Diseases, University of Verona, Verona, Italy.ORCID 0000-0003-2010-4977
Theoklis ZaoutisCollaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.ORCID 0000-0003-0127-6562
Oliver A CornelyFaculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.ORCID 0000-0001-9599-3137
Zoi Dorothea PanaSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0002-5893-1081

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe VACCELERATE Pan-European Scientific network aims to strengthen the foundation of vaccine trial research across Europe by following the principles of equity, inclusion, and diversity. The VACCELERATE Volunteer Registry network provides access to vaccine trial sites across the European region and supports a sustainable volunteer platform for identifying potential participants for forthcoming vaccine clinical research.

objectiveThe aim of this study was to approach members of patient advocacy groups (PAGs) across Europe to assess their willingness to register for the VACCELERATE Volunteer Registry and their perspectives related to participating in vaccine trials.

methodsIn an effort to understand how to increase recruitment for the VACCELERATE Volunteer Registry, a standardized survey was developed in English and translated into 8 different languages (Dutch, English, French, German, Greek, Italian, Spanish, and Swedish) by the respective National Coordinator team. The online, anonymous survey was circulated, from March 2022 to May 2022, to PAGs across 10 European countries (Belgium, Cyprus, Denmark, France, Germany, Greece, Ireland, Italy, Spain, and Sweden) to share with their members. The questionnaire constituted of multiple choice and open-ended questions evaluating information regarding participants' perceptions on participating in vaccine trials and their willingness to become involved in the VACCELERATE Volunteer Registry.

resultsIn total, 520 responses were collected and analyzed. The PAG members reported that the principal criteria influencing their decision to participate in clinical trials overall are (1) the risks involved, (2) the benefits that will be gained from their potential participation, and (3) the quality and quantity of information provided regarding the trial. The survey revealed that, out of the 520 respondents, 133 individuals across all age groups were "positive" toward registering in the VACCELERATE Volunteer Registry, with an additional 47 individuals reporting being "very positive." Respondents from Northern European countries were 1.725 (95% CI 1.206-2.468) times more likely to be willing to participate in the VACCELERATE Volunteer Registry than respondents from Southern European countries.

conclusionsFactors discouraging participants from joining vaccine trial registries or clinical trials primarily include concerns of the safety of novel vaccines and a lack of trust in those involved in vaccine development. These outcomes aid in identifying issues and setbacks in present registries, providing the VACCELERATE network with feedback on how to potentially increase participation and enrollment in trials across Europe. Development of European health communication strategies among diverse public communities, especially via PAGs, is the key for increasing patients' willingness to participate in clinical studies.

Indexed as

Patient AdvocacyVaccinesClinical Trials as TopicEuropeFranceGermanyHumansVaccinesclinical trialclinical trialsCOVID-19health advocatehealthcarehealth promotionpatient advocacy groupspublic healthVACCELERATEvaccinesvaccine trialvolunteer registry

Identifiers

PMID38573762
PMCPMC10996911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.